Register to get free articles
Want unlimited access? View Plans
Already have an account? Sign in
Xeinadin’s owner Exponent has reportedly appointed advisers from the investment bank Evercore to oversee the £800m sale of the mid-market accounting firm, according to the Times.
Evercore is expected to launch a formal auction for the business in the coming weeks.
The potential price tag comes as sources familiar with the matter revealed to the Times that Xeinadin, which employs around 2,000 people, is pitching EBITDA of about £60m.
Several bankers also stated that good accounting firms can fetch an EBITDA “multiple of 14 times their profitability”, potentially valuing Xeinadin at more than £840m. However, it is said others warned the final sale price was likely to be lower than that valuation.
Founded in 2019, Xeinadin now operates more than 130 offices across London, Yorkshire, the Midlands and Ireland. Since acquiring a stake in 2021, Exponent has expanded the group by acquiring and integrating additional firms under the Xeinadin brand.
The group most recently acquired Irish accountancy firm KBG Accountants, marking the firm’s largest acquisition in Ireland to date.
The move reinforces Xeinadin’s continued investment in the Irish market, KBG is the second firm to join Xeinadin in 2025 with Dublin based Warren and Partners joining in March this year.
Xeinadin and Exponent have been contacted for comment.
